CGX-926
Asset
Corrects mutated MC4R folding and trafficking, restoring receptor function.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- MC4R
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Genetic obesity due to MC4R deficiency
Phase 1, congruencetx.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.